Clinical Trial

Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the effect of multiple doses of vanzacaftor/tezacaftor/deutivacaftor (VNZ/TEZ/D-IVA) on the PK of rosuvastatin and the safety and tolerability of coadministration of VNZ/TEZ/D-IVA with rosuvastatin.
Protocol Amendment History 2 changes
critical Trial completed 2026-04-03
notable Primary completion moved earlier: 2026-04-04 -> 2026-02-28 2026-04-03
Trial Details
NCT Number NCT07349394
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Cystic Fibrosis
Enrollment 18 participants
Start Date 2026-01-12
Primary Completion 2026-02-28 (estimated)
Study Completion 2026-03-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-02